FHS
0.002
100%
LIB
0.002
-33.3%
AHNDA
0.09
76.5%
PER
0.003
-25%
AMD
0.005
66.7%
MHM
0.12
-17.2%
BLU
0.004
33.3%
SHO
0.039
-17%
JCS
0.04
33.3%
CCX
0.054
-16.9%
TAT
0.026
30%
BTN
0.015
-16.7%
PET
0.006
20%
GNM
0.035
-16.7%
AHF
0.019
18.8%
IPD
0.005
-16.7%
CYG
0.395
17.9%
XRA
0.18
-16.3%
BSR
0.34
17.2%
EM3
0.12
-15.5%
RFT
0.007
16.7%
CPO
0.011
-15.4%
CHL
0.19
15.2%
REE
0.011
-15.4%
EMC
0.115
15%
AXQ
4.61
-15.1%
BUX
0.047
14.6%
AON
0.047
-14.5%
LCL
0.008
14.3%
4DX
3.245
-14.4%
ALB
0.051
13.3%
BNL
0.006
-14.3%
CDE
0.009
12.5%
EXT
0.006
-14.3%
D3E
0.345
11.3%
FEL
0.006
-14.3%
88E
0.02
11.1%
PL9
0.006
-14.3%
SER
0.15
11.1%
PNT
0.006
-14.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Neuren Pharmaceuticals Limited (ASX:NEU): Reports top-line results from its Phase 2 clinical trial

Neuren Pharmaceuticals Limited (ASX:NEU) has reported top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Angelman syndrome.

🩺 Clinician and caregiver global efficacy measures specifically designed for Angelman syndrome showed a level of improvement
💊 NNZ-2591 was safe and well tolerated as an oral liquid dose, with no serious adverse events
⚕️Results further strengthen confidence in potential of NNZ-2591 for multiple neurodevelopmental disorders

ASX announcement ⚡ https://announcements.asx.com.au/asxpdf/20240809/pdf/066gd3hmzlyp3z.pdf Jon Pilcher